Global Cytomegalovirus Retinitis Market 2014-2018
出 版 商：Infiniti Research
出版日期：2014/08/13
頁 數：52頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 2,800 (Multi-User License)
USD 3,500 (Global-User License)
USD 2,800 (Multi-User License)
USD 3,500 (Global-User License)
About Cytomegalovirus Retinitis
Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative organism of this disease is cytomegalovirus, a herpes virus that attacks the photosensitive cells in the retina. This disease can lead to permanent blindness if left untreated. It affects one eye initially but spreads to the other eye if neglected. The virus is very commonly found in humans but stays dormant. It usually affects a person with weakened immune system such as HIV-positive patients. There are two forms of cytomegalovirus retinitis: indolent form and fulminant form. Some of the common symptoms of cytomegalovirus retinitis are blurred vision, seeing floaters, photophobia, and blind spots.
TechNavio's analysts forecast the Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis.
TechNavio's report, the Global Cytomegalovirus Retinitis market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cytomegalovirus Retinitis market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ F. Hoffmann-La Roche
‧ Gilead Sciences
‧ Hospira
‧ Shire
Other Prominent Vendors
‧ Auritec Pharmaceuticals
‧ Chimerix Pharmaceuticals
‧ Isis Pharmaceuticals
‧ pSivida
‧ Sanofi
Market Driver
‧ Presence of Unmet Needs
‧ For a full, detailed list, view our report
Market Challenge
‧ Lack of Approved Treatment Guidelines by the World Health Organization
‧ For a full, detailed list, view our report
Market Trend
‧ Increase in Combination Therapies
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative organism of this disease is cytomegalovirus, a herpes virus that attacks the photosensitive cells in the retina. This disease can lead to permanent blindness if left untreated. It affects one eye initially but spreads to the other eye if neglected. The virus is very commonly found in humans but stays dormant. It usually affects a person with weakened immune system such as HIV-positive patients. There are two forms of cytomegalovirus retinitis: indolent form and fulminant form. Some of the common symptoms of cytomegalovirus retinitis are blurred vision, seeing floaters, photophobia, and blind spots.
TechNavio's analysts forecast the Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis.
TechNavio's report, the Global Cytomegalovirus Retinitis market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cytomegalovirus Retinitis market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ F. Hoffmann-La Roche
‧ Gilead Sciences
‧ Hospira
‧ Shire
Other Prominent Vendors
‧ Auritec Pharmaceuticals
‧ Chimerix Pharmaceuticals
‧ Isis Pharmaceuticals
‧ pSivida
‧ Sanofi
Market Driver
‧ Presence of Unmet Needs
‧ For a full, detailed list, view our report
Market Challenge
‧ Lack of Approved Treatment Guidelines by the World Health Organization
‧ For a full, detailed list, view our report
Market Trend
‧ Increase in Combination Therapies
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Route of Administration
07.1.1 Systemic
07.1.2 Ocular
08. Market Segmentation by Dosage Form
08.1.1 Capsule
08.1.2 Implant
08.1.3 Solution
08.1.4 Tablet
09. Market Assessment of Valcyte
10. Rate of Incidence and Prevalence
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2013
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 Hospira
20.1.1 Business Overview
20.1.2 Business Segmentation
20.1.3 Key Information
20.1.4 SWOT Analysis
20.2 Gilead Sciences
20.2.1 Business Overview
20.2.2 SWOT Analysis
20.3 Roche
20.3.1 Business Overview
20.3.2 Business Segmentation
20.3.3 Key Information
20.3.4 SWOT Analysis
20.4 Shire
20.4.1 Business Overview
20.4.2 Key Information
20.4.3 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Cytomegalovirus Retinitis Market 2013-2018 (US$ million)
Exhibit 3: Global Cytomegalovirus Retinitis Market Segmentation by Route of Administration
Exhibit 4: Global Cytomegalovirus Retinitis Market Segmentation by Dosage Form
Exhibit 5: Timeline of Valcyte in the US and EU
Exhibit 6: Quarterly Sales of Valcyte 2013 (US$ million)
Exhibit 7: Quarterly Sales of Valcyte in the US 2013 (US$ million)
Exhibit 8: Quarterly Sales of Valcyte in Europe 2013 (US$ million)
Exhibit 9: Global Cytomegalovirus Retinitis Market by Geographical Segmentation
Exhibit 10: Business Segmentation of Hospira Inc.
Exhibit 11: Business Segmentation of F. Hoffmann La Roche Ltd.
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Route of Administration
07.1.1 Systemic
07.1.2 Ocular
08. Market Segmentation by Dosage Form
08.1.1 Capsule
08.1.2 Implant
08.1.3 Solution
08.1.4 Tablet
09. Market Assessment of Valcyte
10. Rate of Incidence and Prevalence
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2013
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 Hospira
20.1.1 Business Overview
20.1.2 Business Segmentation
20.1.3 Key Information
20.1.4 SWOT Analysis
20.2 Gilead Sciences
20.2.1 Business Overview
20.2.2 SWOT Analysis
20.3 Roche
20.3.1 Business Overview
20.3.2 Business Segmentation
20.3.3 Key Information
20.3.4 SWOT Analysis
20.4 Shire
20.4.1 Business Overview
20.4.2 Key Information
20.4.3 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Cytomegalovirus Retinitis Market 2013-2018 (US$ million)
Exhibit 3: Global Cytomegalovirus Retinitis Market Segmentation by Route of Administration
Exhibit 4: Global Cytomegalovirus Retinitis Market Segmentation by Dosage Form
Exhibit 5: Timeline of Valcyte in the US and EU
Exhibit 6: Quarterly Sales of Valcyte 2013 (US$ million)
Exhibit 7: Quarterly Sales of Valcyte in the US 2013 (US$ million)
Exhibit 8: Quarterly Sales of Valcyte in Europe 2013 (US$ million)
Exhibit 9: Global Cytomegalovirus Retinitis Market by Geographical Segmentation
Exhibit 10: Business Segmentation of Hospira Inc.
Exhibit 11: Business Segmentation of F. Hoffmann La Roche Ltd.
